Combined Hepatocellular and Cholangiocarcinoma

• CLINICAL_TRIALS trial_result · 2023-12-19
  Clinical Trial Update: Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma [Phase 2]

  Phase 2 trial of derazantinib in FGFR2-altered intrahepatic cholangiocarcinoma and related conditions completed; results posted in 2023.